Clin Cancer Res: The SYSUCC-002 study by Professor Zhongyu Yuan Zhongyu's team confirms that first-line trastuzumab + endocrine therapy is non-inferior to trastuzumab + chemotherapy in patients with HR+HER2+ metastatic breast cancer

For first-line treatment of patients with hormone receptor (HR)-positive (HR+) and HER2-positive (HER2+) metastatic breast cancer (MBC), there is currently no evidence that endocrine therapy or chemotherapy combined with anti-HER2 therapy is better treatment strategy
.

The SYSUCC-002 study was an open-label, non-inferiority, phase III randomized controlled trial (NCT01950182) conducted in nine hospitals in China
.

A total of 392 patients were included and randomly divided into trastuzumab + endocrine therapy group (ET group, n = 196) and trastuzumab + chemotherapy group (CT group, n = 196)
.

After a median follow-up of 30.
2 months [interquartile range (IQR) 15.
0-44.
7], the median progression-free survival (PFS) was 19.
2 months in the ET group [95% confidence interval (CI) 16.
7 to 21.
7] in the CT group The median progression-free survival (PFS) was 14.
8 months (12.
8 16.
8) (HR=0.
88; 95% CI, 0.
71 1.
09; P noninferiority <0.
0001)
.

PFS

OS

PFS subgroup analysis

There was no significant difference in ORR between the CT group and the ET group (42.

The incidence of toxicity was significantly higher in the CT group compared with the ET group

AEs

In conclusion, the SYSUCC-002 study confirmed that first-line trastuzumab + endocrine therapy was non-inferior to trastuzumab + chemotherapy in patients with HR+HER2+ metastatic breast cancer

Original source:

Hua X, Bi XW, Zhao JL, Shi YX, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C , An X, Zhong YY, Wang SS, Huang JJ, Yuan ZY; South China Breast Cancer Group (SCBCG).